Zetomipzomib is under investigation in clinical trial NCT04033926 (A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis). The directory classifies it as a under development API with a biotechnology source/manufacturing origin. Other names for this substance include GTPL10409 and GLXC-20150. Its PubChem CID is 117607904.
Zetomipzomib
| CAS No | 1629677-75-3 |
|---|---|
| Molecular Formula | C30H42N4O8 |
| Molecular Weight | 586.70 g/mol |
| Synonyms | (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Zetomipzomib is under investigation in clinical trial NCT04033926 (A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis).
The listed CAS number is 1629677-75-3.
The listed molecular formula is C30H42N4O8.
The listed molecular weight is 586.70 g/mol.
(2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide.
The source lists GTPL10409 and GLXC-20150.